Prelude Therapeutics (PRLD) Retained Earnings (2019 - 2026)
Prelude Therapeutics (PRLD) reported Retained Earnings of -$693.4 million for Q1 2026, down 5778816.67% on a YoY basis from N/an in Q1 2025, and down 1.52% sequentially from -$683.1 million in Q4 2025.
Prelude Therapeutics (PRLD) Retained Earnings (2019 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 8 years of Retained Earnings data on file, last reported at -$693.4 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 5778816.67% year-over-year to -$693.4 million; the trailing twelve-month figure through Mar 2026 stood at -$693.4 million (down 5778816.67% YoY), and the FY2025 full-year result was -$683.1 million, down 17.05% from the prior year.
- Retained Earnings retreated to -$693.4 million in Q1 2026, from -$683.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $12000.0 in Q1 2025 to a low of -$693.4 million in Q1 2026.
- A 5-year average of -$351.3 million and a median of -$423.3 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings surged 100.0% in 2025 and slumped 5778816.67% in 2026, its largest moves.
- Tracing PRLD's Retained Earnings over 5 years: stood at -$334.6 million in 2022, then slumped by 36.42% to -$456.4 million in 2023, then decreased by 27.86% to -$583.6 million in 2024, then decreased by 17.05% to -$683.1 million in 2025, then decreased by 1.52% to -$693.4 million in 2026.
- Business Quant data shows PRLD's Retained Earnings at -$693.4 million in Q1 2026, -$683.1 million in Q4 2025, and $2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - | -693.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -693.45 Mn |
| Dec 31, 2025 | -683.06 Mn |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | -646.90 Mn |
| Mar 31, 2025 | 12,000.00 |
| Dec 31, 2024 | -583.56 Mn |
| Sep 30, 2024 | -554.83 Mn |
| Jun 30, 2024 | -522.60 Mn |
| Mar 31, 2024 | -487.82 Mn |
| Dec 31, 2023 | -456.39 Mn |
| Sep 30, 2023 | -423.30 Mn |
| Jun 30, 2023 | -711,000.00 |
| Mar 31, 2023 | -398,000.00 |
| Dec 31, 2022 | -334.56 Mn |
| Sep 30, 2022 | -305.90 Mn |
| Jun 30, 2022 | -275.96 Mn |
| Mar 31, 2022 | -2.31 Mn |
| Dec 31, 2021 | -711,000.00 |
| Sep 30, 2021 | -186.28 Mn |
| Jun 30, 2021 | -155.60 Mn |